Please use this identifier to cite or link to this item:
Title: Effects of chronic renal failure on the pharmacokinetics of ruboxistaurin and its active metabolite 338522
Authors: Wise, S.
Yuen, E.
Chan, C.
Yeo, K.P. 
Teng, L.
Lau, T.
Voelker, J.
Issue Date: 2006
Citation: Wise, S., Yuen, E., Chan, C., Yeo, K.P., Teng, L., Lau, T., Voelker, J. (2006). Effects of chronic renal failure on the pharmacokinetics of ruboxistaurin and its active metabolite 338522. Clinical Pharmacokinetics 45 (3) : 297-303. ScholarBank@NUS Repository.
Abstract: Background: Ruboxistaurin, a specific inhibitor of the β1 and β2 isoforms of Abstract protein kinase C, is currently in clinical development for the treatment of several diabetic microvascular complications. The major metabolite, N-desmethyl ruboxistaurin (metabolite 338522), is equipotent in its inhibitory activity. The elimination of ruboxistaurin and its metabolites is primarily through bile and the faecal route, with urinary excretion constituting only a minor route. Objective: To assess the effects of chronic renal insufficiency on the pharmacokinetics of ruboxistaurin and metabolite 338522. Methods: Six healthy subjects (creatinine clearance >80 mL/min/1.73m2) and six end-stage renal disease (ESRD) subjects requiring long-term haemodialysis were studied. All subjects received a single oral dose of ruboxistaurin 32mg followed by serial blood sampling up to 72 hours. ESRD subjects underwent haemodialysis approximately 58 hours after dosing, with blood samples obtained immediately before and after dialysis. Results: No differences were observed in the pharmacokinetic parameters (area under the plasma concentration-time curve from time zero to infinity [AUC∞], maximum plasma concentration [Cmax] and elimination half-life [t1/2]) of ruboxistaurin and metabolite 338522 between healthy and ESRD subjects Plasma concentrations of ruboxistaurin were below the lower limit of quantification by the time of haemodialysis. The predicted post-dialysis plasma concentrations of metabolite 338522 were not statistically different from the observed values (p = 0.163). Ruboxistaurin was well tolerated in both groups of subjects. Conclusion: These results indicate that the kidney is not an important route of metabolism or excretion for ruboxistaurin and metabolite 338522. Based on the pharmacokinetic and tolerability findings, no formal dosage adjustment of ruboxistaurin should be required for patients with any degree of renal impairment who are undergoing haemodialysis. © 2006 Adis Data Information BV. All rights reserved.
Source Title: Clinical Pharmacokinetics
ISSN: 03125963
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.


checked on Mar 13, 2018


checked on Dec 19, 2018

Page view(s)

checked on May 12, 2022

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.